Eli Lilly and Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the United States and strengthen the domestic medicine supply chain, the companies announced.
The investment is expected to increase production of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region.
This investment will boost domestic production and create 400 high-skilled jobs in Ohio.
The manufacturing operations will include Lilly's KwikPen injectable device, used for treating diabetes and obesity. The multi-year partnership, which began in 2023, has already produced more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats.
This partnership reflects Lilly's efforts to meet rising demand for its medicines.
Lilly's US capital expansion commitments since 2020 total more than $55 billion, and the company plans to break ground on several recently announced US manufacturing sites this year. The announcement comes as the Trump administration moves to impose 100% tariffs on branded drugs unless companies reduce prices or manufacture medicines domestically.